**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 7121**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (12): **Nonalcoholic fatty liver disease**

**Epidemiology of fatty liver: An update**

Bedogni *et al.* Epidemiology of fatty liver

Giorgio Bedogni, Valerio Nobili, Claudio Tiribelli

**Giorgio Bedogni**, **Claudio Tiribelli**, Liver Research Center, Fondazione Italiana Fegato-ONLUS, 34013 Trieste, Italy

**Giorgio Bedogni**, International Center for the Assessment of Nutritional Status, University of Milan, 20126 Milan, Italy

**Valerio Nobili**, Liver Research Unit, Bambino Gesù Children’s Hospital, IRCCS, 00149 Rome, Italy

**Claudio Tiribelli**, Department of Medical Sciences, University of Trieste, 34013 Trieste, Italy

**Author contributions:** All the authors contributed to this paper equally.

**Correspondence to: Giorgio Bedogni, MD,** Clinical Epidemiology Unit, Liver Research Center, Fondazione Italiana Fegato-ONLUS, Building Q Strada Statale 14 – km 163.5, 34013 Trieste, Italy. giorgiobedogni@gmail.com

**Telephone:** +39-522-1714445 **Fax:** +39-522-841949

**Received:** November 4, 2013 **Revised:** January 14, 2014

**Accepted:** February 17, 2014

**Published online:**

**Abstract**

We provide a concise review of the main epidemiological literature on fatty liver (FL) published between January 2011 and October 2013. The findings from such literature will be considered in light of the already available knowledge. We discuss the limitations inherent into the dichotomization of FL into non-alcoholic and alcoholic FL, the potential relevance of FL as independent predictor of cardiometabolic disease, and recent research addressing the role of FL as independent predictor of mortality. This review is organized as a series of answers to relevant questions about the epidemiology of fatty liver.

©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Fatty liver; Epidemiology

**Core tip:** We discuss the limitations inherent into the dichotomization of FL into non-alcoholic and alcoholic FL, the potential relevance of FL as independent predictor of cardiometabolic disease, and recent research addressing the role of FL as independent predictor of mortality.

Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update.

**Available from:**

**DOI:**

**INTRODUCTION**

The aim of this paper is to provide a concise review of the main epidemiological literature on fatty liver (FL) published between January 2011 and October 2013. The findings from such literature will be considered in light of the already available knowledge[1,2]. Our main focus will be the general population even if we will consider also selected clinical studies. We have organized this paper as a series of answers to relevant questions about the epidemiology of FL. It is our hope that this format will attract the interest of practicing physicians as did our previous review on FL that was organized in this manner [3].

**WHAT IS FATTY LIVER?**

A liver is said to be “fatty” when its hepatocytes contain more than 5% of triglycerides[4,5].

The reference method for the diagnosis of FL is liver biopsy (LB), which is presently used to classify steatosis as light (5% to 33%), moderate (> 33% and < 66%) or severe (> 66%)[4,5]. Although LB is the reference method for the diagnosis of FL, it is an imperfect gold-standard because of sampling error[6,7]. More importantly, LB cannot be employed outside Liver Centers, and less invasive methods are needed to study the epidemiology of FL in the general population[8].

Liver ultrasonography (LUS) is the method most commonly employed to assess FL in the general population[8-11]. As compared to LB, LUS has a sensitivity of 84.8%, a specificity of 93.6%, a positive likelihood ratio of 13.3, and a negative likelihood ratio of 0.16 for the detection of moderate to severe FL[11]. LUS offers an accurate assessment of FL starting from an intrahepatic triglyceride content of 10%[11]. We have found LUS to agree well with LB for the assessment of moderate to severe FL in children[12] but there are presently not enough data to draw definitive conclusions about the interchangeability of LUS and LB in pediatric age[13,14].

Magnetic resonance spectroscopy of the liver (LMRS) has also been used to perform population studies of FL[15] but is less portable and more expensive than LUS[8]. However, a clear advantage of LMRS over LUS is that it offers a continuous rather than an ordinal measure of FL[16].

A further option to study FL in the general population is the use of surrogate markers. A discussion of such markers is beyond the scope of this article and the interested reader is referred to a recent review on this topic[8]. We wish however to briefly mention the fatty liver index (FLI), which we developed in about 500 adult citizens of Campogalliano (Modena, Northern Italy) during the Dionysos Nutrition and Liver Study[9,17]. FLI is based on four common anthropometric and biochemical measures (body mass index, waist circumference, gamma-glutamyl-transferase and triglycerides) and has gained much attention because of its association with prevalent cardiovascular disease, incident type 2 diabetes mellitus (T2DM), and liver-related mortality[18-22]. More importantly for its ability to serve as surrogate marker of FL, FLI has been successfully cross-validated in external populations[23,24].

**WHAT IS NON-ALCOHOLIC FATTY LIVER (DISEASE)?**

FL is usually dichotomized into alcoholic fatty liver (AFL) and non-alcoholic fatty liver (NAFL)[3,25].

NAFL is however just one part of the spectrum of liver disease that falls under the umbrella term of non-alcoholic fatty liver disease (NAFLD)[3]. It should be noted that we are using the term NAFL in a broader sense than that recently suggested by the American Gastroenterological Association (AGA), *i.e.*, the finding of “steatosis without steatohepatitis” at LB[26].

Besides NAFL, the NAFLD spectrum includes steato-hepatitis (NASH), fibrosis, cirrhosis and hepatocarcinoma (HCC). The idea behind NAFLD as a spectrum of liver disease was that simple steatosis might progress to NASH and then to chronic liver disease. However, this idea has been increasingly challenged in the last decade[27]. Studies performed in Liver Centers have shown that, whereas about 20% of cases of NASH will develop liver fibrosis, simple steatosis will virtually never progress to NASH[1,2,28]. There is indeed the possibility that NAFL and NASH are twin but independent conditions and that triglyceride accumulation alone is protective, at least up to a certain degree and as long as liver outcomes are concerned[27,29].

NAFL(D) and AFL(D) cannot be distinguished at LB and their differentiation is based on the assessment of ethanol intake[3,25]. After exclusion of other causes of FL (mostly hepatitis B or hepatitis C virus infection and use of steatogenic drugs), the guidelines of the European Association for the Study of the Liver (EASL) suggest that NAFLD should be diagnosed when ethanol intake is ≤ 20 g/d in women and ≤ 30 g/din men[30]. AGA guidelines suggest that NAFLD should be diagnosed when men consume ≤ 21 drinks per weekand women consume ≤ 14 drinks per week[26]. Although the EASL and AGA cut-points are roughly equivalent, the former have the advantage of focusing on actual ethanol intake, possibly avoiding the problems associated with the choice of different “drink units”[31].

The NAFL(D) *vs* AFL(D) dichotomization is vulnerable to many critiques[25]. Besides the obvious loss of information[32], the most important critique is that such dichotomization hides the fact that obesity and alcohol interact in determining the prevalence and incidence of FL[25,33,34]. From a public health perspective, it is more useful to study the effect of alcohol intake on FL-related outcomes independently from other risk factors rather than dichotomizing FL more or less arbitrarily into NAFL and AFL[10,17,25]. Another problem is that such dichotomization assumes the use of an instrument accurate enough to detect small differences in ethanol intake. Even the 7-day weighted food record method that we employed in the Dionysos Nutrition & Liver study may not be accurate enough to detect such differences[9].

**WHAT IS THE PREVALENCE OF FATTY LIVER?**

FL is the most common liver disease in Western countries and NAFLD is the most common reason of altered liver enzymes in primary care practice[30].

In the general population of the Dionysos Nutrition and Liver Study, 45% of individuals had (any degree of) FL at LUS[9,17]. Using a cut-point of 20 g/d for ethanol intake, 25% of them had NAFLD and 20% had AFLD[9]. A recent study performed in a large primary care practice has shown that nearly one every three patients with persistently elevated alanine transaminase has NAFLD[37,38].

Systematic reviews estimate that about 20%-30% of individuals in Western countries have NAFLD[26] and similar figures are being increasingly provided for Eastern countries[39]. The prevalence of NAFLD increases with age, is highest in males between 40 and 65 years and is higher in Hispanics and lower in African-Americans[26,30,35]. The prevalence of NAFLD is increasing rapidly among children in parallel with the current epidemic of obesity[36].

LUS data from the third edition of the National Health and Nutrition Examination Survey (NHANES III) (1988-1994) have recently been used to provide an estimate of the prevalence of FL in the general United States population[40]. Although these data were collected more than 20 years ago and may underestimate the present prevalence of FL, they are unique because they were obtained in a representative sample of the general population. The age-adjusted prevalence of FL in NHANES III, defined as moderate to severe FL at LUS, was 21% while that of NAFLD was 20%[40].

Because LB can be performed only in Liver Centers, it is unknown how many individuals in the general population have NASH or liver fibrosis. Projections made mostly on the basis of autopsy data suggest that 3%-5% of individuals in the general population might have NASH[2,41]. Using surrogate markers of liver fibrosis, it has been postulated that about 3% of individuals in the general population might have liver fibrosis[42].

**WHAT IS THE INCIDENCE OF FATTY LIVER?**

The incidence of LUS-determined FL (any degree) in the Dionysos Study was 2/100/years[10] but values of up to 10/100/years have been reported by other studies employing the same method[2,30].

**WHAT IS THE NATURAL HISTORY OF FATTY LIVER?**

Systematic reviews of studies performed in tertiary care centers have clearly shown that NASH is a risk factor for liver fibrosis, cirrhosis and HCC [1,2,28]. However, as determined by LUS, most cases of FL in the general population regress, especially in the presence of weight loss[10,43,44].

A recent longitudinal analysis of about 11000 individuals from NHANES III has shown that LUS-determined NAFLD alone is not an independent predictor of mortality[45]. However, when considered together with advanced fibrosis – as detected by surrogate markers – NAFLD was associated with increased mortality independently of known risk factors[45]. Another recent analysis of the same NHANES III data (with a different number of subjects because of different inclusion criteria) has shown that NAFLD may be an independent predictor of liver-related mortality in Whites[46]. Considering the different effect measures and statistical methods employed by these studies[45,46], their results are not necessarily at odds if one considers that the effect size of the “positive” study was highly variable (relative risk of death attributable to NAFLD = 10.74, 95%CI: 1.17-98.54).

**WHAT IS THE RELATIONSHIP BETWEEN FATTY LIVER AND THE METABOLIC SYNDROME?**

There is no doubt that NAFLD is more common among obese individuals and those with the metabolic syndrome (MS)[26,30]. Because of this association, it has become common to state that NAFLD is the “hepatic component” of the MS[46]. However, this hypothesis has not undergone formal testing until very recently[47]. A confirmatory factor analysis of NHANES III cross-sectional data has indeed shown that NAFLD is more likely to be a separate entity rather than an additional component of MS[47]. Even if NAFLD is not the “hepatic component” of MS, however, it remains to be tested whether MS and NALFD contribute independently to “hard outcomes” in the general population. This is important also in view of the ongoing controversy about the clinical relevance of the MS concept[48-50].

Although NAFLD is most commonly associated with obesity, it is by no means uncommon in lean individuals. A recent analysis of NHANES III data has shown that the prevalence of NAFLD in lean individuals – defined as those with body mass index ≤ 25 kg/m2 – is one fourth of that observed in overweight-obese individuals (7% *vs* 28%)[35]. As compared to its overweight-obese counterpart, “lean NAFLD” is characterized by younger age, higher insulin sensitivity and lower frequency of MS[35].

**WHAT IS THE RELATIONSHIP BETWEEN FATTY LIVER AND CARDIOMETABOLIC DISEASE?**

Much of the popularity of NAFLD among researchers and clinicians outside the field of hepatology stems from its association with cardiometabolic disease[51-53].

In the last few years, an increasing number of cohort studies performed in the general population of Western and Eastern countries has shown that NAFLD – as diagnosed by LUS or by surrogate markers such as the FLI – is independently associated with incident T2DM[18,21,54,55]. The available evidence pointing to an association between NAFLD and incident cardiovascular disease (CVD) is presently of lower quality than that available for incident T2DM[54]. In a recent study performed in a tertiary CVD care center, NAFLD was associated with coronary artery disease but not with cardiovascular mortality[56]. Likewise, a recent analysis of NHANES III cohort data showed that NAFLD was associated with incident CVD but not with CVD mortality[57].

The availability of long-term follow-up data in more or less representative samples of the general population will be central in coming years to improve our understanding of the NAFLD-CVD relationship.

**REFERENCES**

1 **Musso G**, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011; **43**: 617-649 [PMID: 21039302 DOI: 10.3109/07853890.2010.518623]

2 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]

3 **Bedogni G**, Bellentani S. Fatty liver: how frequent is it and why? *Ann Hepatol* 2004; **3**: 63-65 [PMID: 15257248]

4 **Brunt EM**. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. *Dig Dis* 2012; **30 Suppl 1**: 61-68 [PMID: 23075870 DOI: 10.1159/000341127]

5 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

6 **Ratziu V**, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. *Aliment Pharmacol Ther* 2007; **26**: 821-830 [PMID: 17767466 DOI: 10.1111/j.1365-2036.2007.03425.x]

7 **Ratziu V**, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* 2005; **128**: 1898-1906 [PMID: 15940625 DOI: 10.1053/j.gastro.2005.03.084]

8 **Festi D**, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. *Aliment Pharmacol Ther* 2013; **37**: 392-400 [PMID: 23278163 DOI: 10.1111/apt.12186]

9 **Bedogni G**, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; **42**: 44-52 [PMID: 15895401 DOI: 10.1002/hep.20734]

10 **Bedogni G**, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. *Hepatology* 2007; **46**: 1387-1391 [PMID: 17685472 DOI: 10.1002/hep.21827]

11 **Hernaez R**, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011; **54**: 1082-1090 [PMID: 21618575 DOI: 10.1002/hep.24452]

12 **Shannon A**, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. *J Pediatr Gastroenterol Nutr* 2011; **53**: 190-195 [PMID: 21788761 DOI: 10.1097/MPG.0b013e31821b4b61]

13 **Vajro P**, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, Durmaz O, Lacaille F, McLin V, Nobili V. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. *J Pediatr Gastroenterol Nutr* 2012; **54**: 700-713 [PMID: 22395188 DOI: 10.1097/MPG.0b013e318252a13f]

14 **Awai HI**, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and Recommendations for Imaging Liver Fat in Children, Based on Systematic Review. *Clin Gastroenterol Hepatol* 2013; [Epub ahead of print] [PMID: 24090729 DOI: 10.1016/j.cgh.2013.09.050]

15 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

16 **Qayyum A**. MR spectroscopy of the liver: principles and clinical applications. *Radiographics* 2009; **29**: 1653-1664 [PMID: 19959513 DOI: 10.1148/rg.296095520]

17 **Bedogni G**, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006; **6**: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]

18 **Jung CH**, Lee WJ, Hwang JY, Yu JH, Shin MS, Lee MJ, Jang JE, Leem J, Park JY, Kim HK. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. *Diabet Med* 2013; **30**: 428-435 [PMID: 23278318 DOI: 10.1111/dme.12104]

19 **Kozakova M**, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. *Hepatology* 2012; **55**: 1406-1415 [PMID: 22334565 DOI: 10.1002/hep.25555]

20 **Calori G**, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. *Hepatology* 2011; **54**: 145-152 [PMID: 21488080 DOI: 10.1002/hep.24356]

21 **Balkau B**, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. *BMC Gastroenterol* 2010; **10**: 56 [PMID: 20529259 DOI: 10.1186/1471-230X-10-56]

22 **Gastaldelli A**, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. *Hepatology* 2009; **49**: 1537-1544 [PMID: 19291789 DOI: 10.1002/hep.22845]

23 **Zelber-Sagi S**, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. *World J Gastroenterol* 2013; **19**: 57-64 [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57]

24 **Koehler EM**, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. *Clin Gastroenterol Hepatol* 2013; **11**: 1201-1204 [PMID: 23353640 DOI: 10.1016/j.cgh.2012.12.031]

25 **Völzke H**. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? *World J Gastroenterol* 2012; **18**: 3492-3501 [PMID: 22826613 DOI: 10.3748/wjg.v18.i27.3492]

26 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

27 **Yilmaz Y**. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? *Aliment Pharmacol Ther* 2012; **36**: 815-823 [PMID: 22966992]

28 **Argo CK**, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. *J Hepatol* 2009; **51**: 371-379 [PMID: 19501928 DOI: 10.1016/j.jhep.2009.03.019]

29 **Tilg H**, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; **52**: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]

30 **Ratziu V**, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010; **53**: 372-384 [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008]

31 **MacDonald I**. Health issues related to alcohol consumption. Malden, MA: Blackwell Science Ltd., 1999

32 **Kuss O**. The danger of dichotomizing continuous variables: A visualization. Teaching Statistics 2013; **35**: 78-79 [DOI: 10.1111/test.12006]

33 **Bellentani S**, Tiribelli C, Bedogni G. Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. In: Alcohol, Nutrition, and Health Consequences. Totowa, NJ: Humana Press, 2013: 497-506

34 **Bellentani S**, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med* 2000; **132**: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819-132-2-200001180-00004]

35 **Younossi ZM**, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. *Medicine (Baltimore)* 2012; **91**: 319-327 [PMID: 23117851 DOI: 10.1097/MD.0b013e3182779d49]

36 **Giorgio V**, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. *BMC Pediatr* 2013; **13**: 40 [PMID: 23530957 DOI: 10.1186/1471-2431-13-40]

37 **Armstrong MJ**, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. *J Hepatol* 2012; **56**: 234-240 [PMID: 21703178 DOI: 10.1016/j.jhep.2011.03.020]

38 **Ratziu V**, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. *J Hepatol* 2012; **56**: 23-25 [PMID: 21875499 DOI: 10.1016/j.jhep.2011.08.002]

39 **Fan JG**. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. *J Gastroenterol Hepatol* 2013; **28 Suppl 1**: 11-17 [PMID: 23855290 DOI: 10.1111/jgh.12036]

40 **Lazo M**, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Epidemiol* 2013; **178**: 38-45 [PMID: 23703888 DOI: 10.1093/aje/kws448]

41 **Scaglioni F**, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. *Dig Dis* 2011; **29**: 202-210 [PMID: 21734385 DOI: 10.1159/000323886]

42 **Poynard T**, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, Munteanu M, Drane F, Messous D, Bismut FI, Carrau JP, Massard J, Ratziu V, Giordanella JP. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMC Gastroenterol* 2010; **10**: 40 [PMID: 20412588 DOI: 10.1186/1471-230X-10-40]

43 **Zelber-Sagi S**, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. *World J Gastroenterol* 2011; **17**: 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377]

44 **Zelber-Sagi S**, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *J Hepatol* 2012; **56**: 1145-1151 [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011]

45 **Kim D**, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology* 2013; **57**: 1357-1365 [PMID: 23175136 DOI: 10.1002/hep.26156]

46 **Otgonsuren M**, Stepanova M, Gerber L, Younossi ZM. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. *Dig Dis Sci* 2013; **58**: 1132-1140 [PMID: 23143735 DOI: 10.1007/s10620-012-2446-3]

47 **Smits MM**, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. *J Gastroenterol Hepatol* 2013; **28**: 664-670 [PMID: 23286209 DOI: 10.1111/jgh.12106]

48 **Reaven GM**. The metabolic syndrome: time to get off the merry-go-round? *J Intern Med* 2011; **269**: 127-136 [PMID: 21129047 DOI: 10.1111/j.1365-2796.2010.02325.x]

49 **Simmons RK**, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia* 2010; **53**: 600-605 [PMID: 20012011 DOI: 10.1007/s00125-009-1620-4]

50 **Beckstead JW**, Beckie TM. How much information can metabolic syndrome provide? An application of information theory. *Med Decis Making* 2011; **31**: 79-92 [PMID: 20729508 DOI: 10.1177/0272989X10373401]

51 **Nestel PJ**, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. *Curr Opin Lipidol* 2013; **24**: 1-3 [PMID: 23298957 DOI: 10.1097/MOL.0b013e32835c0834]

52 **Williams KH**, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. *Endocr Rev* 2013; **34**: 84-129 [PMID: 23238855 DOI: 10.1210/er.2012-1009]

53 **Anstee QM**, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]

54 **Ghouri N**, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. *Hepatology* 2010; **52**: 1156-1161 [PMID: 20658466 DOI: 10.1002/hep.23789]

55 **Sung KC**, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. *J Clin Endocrinol Metab* 2013; **98**: 3637-3643 [PMID: 23873989 DOI: 10.1210/jc.2013-1519]

56 **Wong VW**, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. *Gut* 2011; **60**: 1721-1727 [PMID: 21602530 DOI: 10.1136/gut.2011.242016]

57 **Stepanova M**, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. *Clin Gastroenterol Hepatol* 2012; **10**: 646-650 [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039]

**P-Reviewers:** Sanal MG, Shen WJ

**S-Editor:** Zhai HH **L-Editor: E-Editor:**